290 related articles for article (PubMed ID: 22593439)
1. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
[TBL] [Abstract][Full Text] [Related]
2. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
3. Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
Asano M; Matsui J; Towle MJ; Wu J; McGonigle S; DE Boisferon MH; Uenaka T; Nomoto K; Littlefield BA
Anticancer Res; 2018 Jun; 38(6):3375-3385. PubMed ID: 29848686
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
7. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
[TBL] [Abstract][Full Text] [Related]
8. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
[TBL] [Abstract][Full Text] [Related]
9. Eribulin shows high concentration and long retention in xenograft tumor tissues.
Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
[TBL] [Abstract][Full Text] [Related]
10. Eribulin mesylate in patients with refractory cancers: a Phase I study.
Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
[TBL] [Abstract][Full Text] [Related]
11. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
12. Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Ohtani S; Nakayama T; Yoshinami T; Watanabe KI; Hara F; Sagara Y; Kawaguchi H; Higaki K; Matsunami N; Hasegawa Y; Takahashi M; Mizutani M; Morimoto T; Sato M; Itoh M; Morita S; Masuda N
Breast Cancer; 2018 Jul; 25(4):438-446. PubMed ID: 29435730
[TBL] [Abstract][Full Text] [Related]
13. Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
Smith JW; Vukelja S; Hoffman AD; Jones VE; McIntyre K; Berrak E; Song JX; O'Shaughnessy J
Clin Breast Cancer; 2016 Feb; 16(1):31-7. PubMed ID: 26433876
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
15. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 Aug; 60(8):1325-32. PubMed ID: 23553917
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
[TBL] [Abstract][Full Text] [Related]
17. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.
Towle MJ; Salvato KA; Wels BF; Aalfs KK; Zheng W; Seletsky BM; Zhu X; Lewis BM; Kishi Y; Yu MJ; Littlefield BA
Cancer Res; 2011 Jan; 71(2):496-505. PubMed ID: 21127197
[TBL] [Abstract][Full Text] [Related]
18. Advances in therapy: eribulin improves survival for metastatic breast cancer.
Morris PG
Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesylate.
Jain S; Vahdat LT
Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]